Charles Schoch Sells 8,897 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Charles Schoch sold 8,897 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $5.97, for a total value of $53,115.09. Following the transaction, the insider now directly owns 72,404 shares of the company’s stock, valued at approximately $432,251.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Candel Therapeutics Trading Up 10.1 %

NASDAQ:CADL opened at $7.29 on Wednesday. Candel Therapeutics, Inc. has a twelve month low of $0.66 and a twelve month high of $14.30. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.66. The business has a 50 day moving average price of $7.96 and a two-hundred day moving average price of $4.64. The company has a market cap of $216.92 million, a P/E ratio of -5.70 and a beta of -0.94.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.28) earnings per share for the quarter. As a group, analysts expect that Candel Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.